VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (GB:CURE) Price & Chart

Truist raised the firm’s price target on Insulet (PODD) to $160 from $153 and keeps a Hold rating on the shares after its Q3 earnings beat. The company also guided

Illumina (ILMN) announced an expansion of its molecular residual disease, or MRD, research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace amounts of

Roth Capital analyst Max Masucci lowered the firm’s price target on Natera (NTRA) to $405 from $475 and keeps a Buy rating on the shares. The surprising CEO transition has

Piper Sandler raised the firm’s price target on Moderna (MRNA) to $305 from $230 and keeps an Overweight rating on the shares following the company’s earnings report. The firm anticipates

Canaccord analyst David Hynes raised the firm’s price target on Veeva (VEEV) to $315 from $260 and keeps a Hold rating on the shares. The firm said its investor day

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $110 from $130 and keeps a Buy rating on the shares following the Q3 report. Despite the “rapid decline”

BTIG analyst David Larsen raised the firm’s price target on Veeva (VEEV) to $360 from $340 and keeps a Buy rating on the shares. The company’s annual Investor Day event

In recognition of World Diabetes Day on November 14, Insulet (PODD) Corporation announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna (MRNA) to $195 from $137 and keeps a Neutral rating on the shares. Moderna delivered a significant Q3